Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...

Denali Therapeutics (DNLI) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...

Denali Therapeutics (NASDAQ:DNLI – Free Report) had its price objective cut by HC Wainwright from $90.00 to $87.00 in a ...

Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III ...

Fintel reports that on January 7, 2025, Baird initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a Outperform ...

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data ...

BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2 ...

Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The ...

William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for ...

Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal ...

Check the time stamp on this data. Updated AI-Generated Signals for Denali Therapeutics Inc. (DNLI) available here: DNLI.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...